Protalix BioTherapeutics (PLX)

• Market cap: $160M
• 1 day: -1%
• 5 days: 2.06%
• 1 month: -16.81%
• 3 months: -33.56%
• 6 months: 4.76%
• Year to date: 13.79%
• 1 year: 18.56%
• 5 years: -31.49%
• 10 years: -75.25%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Employees: 226